Elevated levels of Ddimer are not uncommon in patients with SARSCoV2 infection,and interpretation of this phenomenon is challenging for clinicians. Pulmonary embolism (PE) is an extremely severe complication and frequent event among patients with COVID19.Objective: to establish the clinical and laboratory features of the course of PE verifiedby computed tomography angiography (CTA) of the pulmonary arteries in a group of individuals with confirmed SARSCoV2 infection and elevated Ddimer levels at the time of admission.Мaterials and methods. Analysis of medical records of 3664 in patients with confirmed SARSCoV2 coronavirus infection, hospitalized at “4th Сity Clinical Hospital named afterN. E. Savchenko” of Minsk in the period from 01.01.2021 to 31.12.2021 was performed,the prevalence of patients with PE and COVID19 was 3.1 % (n = 113). Two groups of patients with confirmed COVID19 with elevated Ddimer level (>500 ng/ml) at the time of admission were defined: the study group (“PE+”) included COVID19 patients with verified PE by CTA (n = 15), the comparison group (“PE–”) included those with PE excluded by CTA (n = 22).Results. The findings showed that individuals with COVID19, elevated Ddimer leveland developed PE at the time of admission had a more marked respiratory insufficiency, higher leukocytosis and neutrophil levels; the proportion of patients with increased prothrombin time (PT) was higher in the “PE+” group compared to the “PE–” group. A moderately strong association between outcome (PE) and elevated PT levels (html5-dom-document-internal-entity2-981-end = 0.43, p < 0.05), elevated leukocyte levels (html5-dom-document-internal-entity2-981-end = 0.34, p < 0.05), direct correlations between a number of inflammatory and hemostasis indicators were found.Conclusion. The findings indicate the presence of COVID19associated coagulopathy in patients with confirmed SARSCoV2 infection and elevated Ddimer level at the time of hospitalization. The pathogenetic basis and thrombogenic risk factors in patients with COVID19 require further clarification.
- 1. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia / N. Tang [et al.] // J Thromb Haemost. – 2020. – Vol. 18, № 4. – P. 844–847.
- 2. Coagulopathy in COVID-19 / T. Iba [et al.] // J. Thromb Haemost. – 2020. – Vol. 18, № 9. – P. 2103–2109.
- 3. Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19) / B. Christensen [et al.] // Semin Thromb Hemost. – 2020. – Vol. 46, № 07. – P. 845–849.
- 4. Endothelial cell infection and endotheliitis in COVID-19 / Z. Varga [et al.] // Lancet. – 2020. – Т. 395, № 10234. – С. 1417–1418.
- 5. COVID-19 and venous thromboembolism: A narrative review / D. E. Angelini [et al.] // Res Pract Thromb Haemost. – 2022. – Т. 6, № 2. – С. e12666.
- 6. Association of inflammatory markers with the severity of COVID-19: A meta-analysis / F. Zeng [et al.] // International Journal of Infectious Diseases. – 2020. – Vol. 96. – P. 467–474.
- 7. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19 / J. S. Berger [et al.] // ATVB. – 2020. – Vol. 40, № 10. – P. 2539–2547.
- 8. Risk factors for pulmonary embolism in patients with COVID-19: a systemic review and meta-analysis / L. Cui [et al.] // International Journal of Infectious Diseases. – 2021. – Vol. 111. – P. 154–163.
- 9. Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis / Y. J. Suh [et al.] // Radiology. – 2021. – Т. 298, № 2. – С. E70–E80.